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HIGHLIGHTS
•	 The OSCAR study evaluated front- line bevacizumab for advanced ovarian cancer in the UK.
•	 Median progression- free survival was 15.4 months and toxicity was predictable and manageable.
•	 Median progression- free survival was shortest in patients who did not undergo surgery.
AbSTRACT
Objective Two randomized phase III trials demonstrated 
the efficacy and safety of combining bevacizumab with 
front- line carboplatin/paclitaxel for advanced ovarian 
cancer. The OSCAR (NCT01863693) study assessed the 
impact of front- line bevacizumab- containing therapy on 
safety and oncologic outcomes in patients with advanced 
ovarian cancer in the UK.
Methods Between May 2013 and April 2015, patients 
with high- risk stage IIIB–IV advanced ovarian cancer 
received bevacizumab (7.5 or 15 mg/kg every  
3 weeks, typically for ≤12 months, per UK clinical practice) 
combined with front- line chemotherapy, with bevacizumab 
continued as maintenance therapy. Co- primary endpoints 
were progression- free survival and safety (NCI- CTCAE 
v4.0). Patients were evaluated per standard practice/
physician’s discretion.
Results A total of 299 patients received bevacizumab- 
containing therapy. The median age was 64 years 
(range 31–83); 80 patients (27%) were aged ≥70 years. 
Surgical interventions were primary debulking in 21%, 
interval debulking in 36%, and none in 43%. Most 
patients (93%) received bevacizumab 7.5 mg/kg with 
carboplatin/paclitaxel. Median duration of bevacizumab 
was 10.5 months(range <0.1–41.4); bevacizumab and 
chemotherapy were given in combination for a median 
of three cycles (range 1–10). Median progression- 
free survival was 15.4 (95% CI 14.5 to 16.9) months. 
Subgroup analyses according to prior surgery showed 
median progression- free survival of 20.8, 16.1, and 
13.6 months in patients with primary debulking, 
interval debulking, and no surgery, respectively. Median 
progression- free survival was 16.1 vs 14.8 months in 
patients aged <70 versus ≥70 years, respectively. The 
1- year overall survival rate was 94%. Grade 3/4 adverse 
events occurred in 54% of patients, the most common 
being hypertension (16%) and neutropenia (5%). Thirty- 
five patients (12%) discontinued bevacizumab for toxicity 
(most often for proteinuria (2%)).
Conclusions Median progression- free survival in this 
study was similar to that in the high- risk subgroup of the 
ICON7 phase III trial. Median progression- free survival was 
shortest in patients who did not undergo surgery.
bACkGROund
Angiogenesis plays a key role in ovarian cancer 
progression and represents an important therapeutic 
target. Several anti- angiogenic agents have been 
evaluated in ovarian cancer; of these, bevacizumab 
is the most extensively studied.1 Bevacizumab is a 
humanized monoclonal antibody that targets vascular 
endothelial growth factor. It is approved in combi-
nation with chemotherapy in newly diagnosed and 
recurrent ovarian cancer by the US Food and Drug 
Administration, the European Medicines Agency, and 
in many other countries worldwide.
The efficacy and safety of front- line bevacizumab, 
carboplatin, and paclitaxel were demonstrated in two 
randomized phase III trials, the Gynecologic Oncology 
Group (GOG)-0218 and the International Collaboration 
on Ovarian Neoplasms (ICON) 7.2 3 Adding bevaci-
zumab to carboplatin and paclitaxel chemotherapy 
significantly improved progression- free survival 
(primary endpoint) in both trials, although no signif-
icant impact on overall survival was detectable in the 
overall population of either trial. Nevertheless, in the 
subgroup of patients classified as ‘high risk’ in ICON7, 
overall survival was significantly improved with beva-
cizumab,4 leading to preferential use of bevacizumab 
in this population in some countries and regions.
Although such trials provide clear evidence of effi-
cacy, typically randomized phase III trials have strict 
eligibility criteria and the populations are often not 
fully representative of patients presenting in routine 
oncology practice.5 It is important to assess whether 
outcomes observed in rigorously conducted random-
ized phase III trials can be replicated in the ‘real- 
world’ setting, where patients typically have more 
comorbidities and are less fit. In England, bevaci-
zumab combined with chemotherapy is reimbursed in 
patients with stage IIIB–IV (high- risk) ovarian cancer, 
based on the significantly improved progression- free 
and overall survival in the ‘high- risk’ subgroup (stage 
III with ≥1 cm residual disease, any stage IV, or no 
surgery) of the ICON7 trial.3 4 The OSCAR study (An 
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Table 1 Baseline characteristics and medical history
Characteristic All patients (n=299)
Subgroup aged
<70 years (n=219)
Subgroup aged
≥70 years (n=80)
Eastern Cooperative Oncology Group performance status, n (%)
  0 81 (27) 65 (30) 16 (20)
  1 99 (33) 70 (32) 29 (36)
  2 20 (7) 13 (6) 7 (9)
  Unknown 99 (33) 71 (32) 28 (35)
Median (range) body mass index, kg/m2 (n=206)
25 (17–50)
(n=147)
24 (17–50)
(n=59)
25 (17–40)
Ongoing hypertension, n (%) 79 (26) 49 (22) 33 (41)
Prior antihypertensive therapy, n (%) 51 (17) 28 (13) 23 (29)
Prior β-blocker therapy, n (%) 27 (9) 14 (6) 13 (16)
Ongoing concomitant medications, n (%)
  Analgesic 219 (73) 170 (78) 49 (61)
  Antibiotic 69 (23) 48 (22) 21 (26)
  Antidepressant 65 (22) 51 (23) 14 (18)
  Antidiabetic 23 (8) 16 (7) 7 (9)
  Diuretic 22 (7) 16 (7) 6 (8)
Histological subtype, n (%*) (n=171) (n=135) (n=36)
  Serous 148 (87) 116 (86) 32 (89)
  Clear cell 8 (5) 7 (5) 1 (3)
  Endometrioid 6 (4) 5 (4) 1 (3)
  Other/missing* 9 (5) 7 (5) 2 (6)
Stage at start of bevacizumab, n (%) (n=298)† (n=218)† (n=80)
  IIIB 15 (5) 11 (5) 4 (5)
  IIIC 152 (51) 104 (48) 48 (60)
  IV 131 (44) 103 (47) 28 (35)
‘High risk’ per Medical Research Council ICON7 
definition‡
268 (90) 199 (91) 69 (86)
Surgery, n (%)
  Primary debulking 62 (21) 48 (22) 14 (18)
  Interval debulking§ 109 (36) 87 (40) 22 (28)
  None 128 (43) 84 (38) 44 (55)
Residual disease after primary debulking surgery, n 
(%)
(n=60)¶ (n=46)¶ (n=14)
  No visible residuum 11 (18) 9 (20) 2 (14)
  <1 cm 9 (15) 8 (17) 1 (7)
  ≥1 cm 40 (67) 29 (63) 11 (79)
*Not mandatory to record data; denominators of 171, 135, and 36, respectively (representing patients for whom surgical records were available, 
although not necessarily including histological information), are used to calculate percentages; ‘other’ includes adenocarcinoma, mixed epithelial, 
mucinous, and papillary, each recorded in one patient.
†Missing in one patient.
‡Stage III with ≥1 cm residuum, any stage IV, or no surgery.
§Including three patients with intended primary surgery who had interval debulking surgery.
¶Details of residual disease missing in two patients.
ICON7, International Collaboration on Ovarian Neoplasms 7.
Observational Study of Avastin (Bevacizumab) in Combination With 
Chemotherapy as First- Line Treatment in Patients With Advanced 
Ovarian Cancer, NCT01863693; sponsored by Roche Products 
Ltd) aimed to determine the safety and efficacy of bevacizumab- 
containing therapy in this patient population in the UK.
MeTHOdS
This single- arm non- interventional study was conducted in accord-
ance with the guidelines for Good Pharmacoepidemiology Practices 
and Good Clinical Practices, in full conformance with the principles 
of the Declaration of Helsinki and the current Guideline for Good 
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Table 2 Treatment exposure
Exposure All patients (n=299)
Subgroup aged
<70 years (n=219)
Subgroup aged
≥70 years (n=80)
Bevacizumab dose, n (%)       
  7.5 mg/kg once every 3 weeks 289 (97) 211 (96) 78 (98)
  15 mg/kg once every 3 weeks 10 (3) 8 (4) 2 (3)
Bevacizumab duration, months       
  Median (range) 10.5 (<0.1–41.4) 10.6 (<1–29.7) 10.4 (<1–41.4)
  >12 months, n (%) 85 (28) 61 (28) 24 (30)
Chemotherapy partner, n (%)       
  Carboplatin+paclitaxel 286 (96) 215 (98) 71 (89)
  Carboplatin alone 11 (4) 2 (1) 9 (11)
  Other* 2 (1) 2 (1) 0
Reason for discontinuing bevacizumab, n (%)     
  Disease progression 134 (45) 95 (43) 39 (49)
  Adverse event 35 (12) 22 (10) 13 (16)
  Investigator’s decision 56 (19) 42 (19) 14 (18)
  Patient’s decision 4 (1) 2 (1) 2 (3)
  Other 3 (1) 2 (1) 1 (1)
  Completed 18 cycles 67 (22) 56 (26) 11 (14)
*Carboplatin+doxorubicin (n=1), oxaliplatin+capecitabine (n=1).
Clinical Practice ICH Tripartite, and in compliance with the current 
European Union Clinical Trial Directive (2001/20/EC), as well as key 
recommendations of the UK Association of the British Pharmaceu-
tical Industry guidance. The protocol and all study- related mate-
rials were approved by the South- East Coast, Brighton and Sussex 
Ethics Committee (12/LO/1680). All patients provided written 
informed consent. There was no patient or public involvement in 
the trial design.
Patients aged ≥18 years with high- risk stage IIIB–IV advanced 
ovarian cancer were eligible provided they had no contraindications 
to bevacizumab and that warnings and precautions for use as spec-
ified in the Summary of Product Characteristics6 were considered. 
Patients received bevacizumab (7.5 or 15 mg/kg every 3 weeks 
typically for up to 12 months, according to UK clinical practice and 
the ICON7 trial3) combined with standard front- line chemotherapy, 
and then continued as single- agent maintenance therapy. The 
choice of chemotherapy regimen was at the treating investigator’s 
discretion. Patients were evaluated according to standard practice 
or at the physician’s discretion during bevacizumab treatment (typi-
cally every 2–3 months according to UK practice), with an end- 
of- study assessment 12 months after the last bevacizumab dose. 
Patients were enrolled between May 2013 and April 2015.
The co- primary objectives were to characterize the safety 
profile of bevacizumab (assessed using National Cancer Institute 
Common Terminology Criteria for Adverse Events, version 4.0) in UK 
routine clinical practice, and to estimate progression- free survival. 
Secondary endpoints included overall survival, objective response 
rate, treatment regimen administered, and quality of life (EuroQol 
5- Dimensions questionnaire, European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire core and 
ovarian cancer modules). Participation in quality of life assessment 
was optional.
There were no predefined hypotheses regarding the primary and 
secondary objectives of the study. The sample size was determined 
based on practical considerations rather than any formal hypoth-
esis testing. Progression- free survival was defined as the interval 
between first dose of front- line therapy until documented disease 
progression. Overall survival was defined as the interval between 
first dose of front- line therapy until death from any cause. Objective 
response rate was assessed locally by investigators and defined as 
the proportion of patients with complete or partial response as best 
response. Subgroup analyses of safety and efficacy according to 
age (<70 vs ≥70 years) were performed.
ReSuLTS
A total of 299 patients from 29 centers in England and Wales 
received bevacizumab- containing therapy. The median age was 
64 years (range 31–83). Eighty patients (27%) were aged ≥70 
years, including nine (3%) ≥80 years. Baseline characteristics and 
medical history are shown in Table  1. Only 57% of patients had 
undergone surgery (primary debulking in 21%, interval debulking 
in 36%). Older patients were less likely than younger patients to 
undergo surgery. Consistent with the high proportion of unoperated 
patients, the vast majority of patients (90%) matched the Medical 
Research Council definition of ‘high risk’ in ICON7.
Most patients (93%) received bevacizumab 7.5 mg/kg every 
3 weeks with carboplatin and paclitaxel. Among the 11 patients 
who received single- agent carboplatin with bevacizumab, five 
were aged ≥80 years, four were 70–80 years, and two were <70 
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Figure 1 Most common adverse events: (A) overall population (any grade in ≥20% of patients and/or grade 3/4 in ≥2% of 
patients); (B) according to age (grade 3/4, occurring in ≥2% of patients in either subgroup).
years. The median duration of bevacizumab therapy was 10.5 
months(range <0.1–41.4), and was similar in subgroups of patients 
aged <70 versus ≥70 years. Bevacizumab was given in combina-
tion with chemotherapy for a median of three cycles (range 1–10). 
In 85 patients (28%), bevacizumab was administered for >12 
months. Table  2 provides further details of treatment exposure. 
At the data cut- off date (14 May 2018), 155 patients (52%) had 
received further chemotherapy, most commonly carboplatin (43%), 
doxorubicin (31%), and paclitaxel (18%).
Almost all patients (99%) experienced at least one adverse 
event. The most common adverse events (any grade) were fatigue 
(48%), constipation (40%), nausea (38%), and hypertension (32%) 
(Figure 1A). Grade 3/4 adverse events occurred in 54% of patients 
(55% of patients aged <70 years vs 54% of those ≥70 years). The 
most common grade ≥3 adverse events were hypertension (16%) 
and neutropenia (5%). Grade 3/4 hypertension was more common 
in older than younger patients (20% vs 15%, respectively) but 
there were no other notable safety differences according to age 
(Figure  1B). There were seven grade 5 adverse events (deaths), 
including one gastrointestinal perforation (see online supplemen-
tary table S1). Two of the patients with a fatal adverse event were 
aged ≥70 years (one case each of bowel obstruction secondary to 
disease progression and aspiration pneumonia).
Table 3 shows adverse events of special interest for bevacizumab 
overall and according to age. The most common type of bleeding 
event was grade 1/2 epistaxis, which occurred in 41 patients 
(14%). Within the category defined as thromboembolic events, the 
most common was pulmonary embolism, which occurred in 13 
patients (4%). Thromboembolic events were more common in older 
than younger patients. Three grade ≥3 adverse events classified 
as gastrointestinal perforation comprised one case each of perfo-
rated appendicitis, enterocutaneous fistula, and gastrointestinal 
perforation. Of note, there were no grade ≥3 cases of congestive 
heart failure, cardiac disorders, posterior reversible encephalopathy 
syndrome, or pulmonary hypertension.
Overall, 35 patients (12%) discontinued bevacizumab because of 
adverse events, most often proteinuria (2%) or pulmonary embolism 
(1%). Only one patient (0.3%) discontinued bevacizumab because 
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Table 3 Adverse events of special interest for bevacizumab
Adverse event, n (%)
All patients (n=299)
Subgroup aged
<70 years (n=219)
Subgroup aged
≥70 years (n=80)
Any grade Grade ≥3 Any grade Any grade
Hypertension 96 (32) 49 (16) 67 (31) 29 (36)
Bleeding 85 (28) 6 (2) 66 (30) 19 (24)
Proteinuria 61 (20) 4 (1) 46 (21) 15 (19)
Thromboembolic event 28 (9) 20 (7) 18 (8) 10 (13)
Thrombocytopenia 24 (8) 4 (1) 15 (7) 9 (11)
Wound- healing complication 6 (2) 1 (<1) 5 (2) 1 (1)
Gastrointestinal perforation 5 (2) 3 (1) 4 (2) 1 (1)
Cardiac disorders* 5 (2) 0 3 (1) 2 (3)
Fistula/abscess 3 (1) 0 1 (<1) 2 (3)
Posterior reversible encephalopathy 
syndrome
0 0 0 0
Congestive heart failure 0 0 0 0
Pulmonary hypertension 1 (<1) 0 1 (<1) 0
*Excluding congestive heart failure and arterial thromboembolic events.
of hypertension. Sixty- seven patients (22%) began new antihyper-
tensive therapy after initiation of bevacizumab- containing therapy. 
Patients with a medical history of hypertension (n=92) were more 
likely than those without a medical history of hypertension (n=207) 
to start new antihypertensive therapy after beginning bevacizumab 
(33% vs 18%, respectively). This effect was particularly pronounced 
in patients aged ≥70 years (46% of patients with a medical history 
of hypertension vs 16% of patients with no history of hypertension).
At the data cut- off date (14 May 2018), progression- free survival 
events had been recorded in 250 patients (84%). The majority of 
these represented progression detected by computed tomography 
(CT) or magnetic resonance imaging (189 patients, 76% of events); 
progression was detected by CA125 elevation alone in 35 patients 
(14%), CA125 elevation subsequently confirmed by CT scan in eight 
patients (3%), physical examination with or without CA125 elevation 
in nine patients (4%), and by histology of cells in the pleural effusion 
in one patient (<1%). Eight patients (3%) died without documented 
progression. Median progression- free survival was 15.4 (95% CI 
14.5 to 16.9) months (Figure  2A). The 1- year progression- free 
survival rate was 68% (95% CI 62% to 73%). Sensitivity analyses 
defining progression- free survival from the date of first interven-
tion (primary surgery or systemic therapy) instead of the protocol 
definition (aligned with ROSiA and ICON7, defining progression- free 
survival from the start of systemic therapy) showed consistent 
results: median progression- free survival was 15.4 (95% CI 14.6 
to 17.2) months.
Subgroup analyses according to prior surgery (Figure 2B) 
showed median progression- free survival of 20.8 
months(95% CI 17.4 to 25.5) in 62 patients who under-
went primary debulking surgery, 16.1 months (95% CI 14.6 
to 19.4) in 109 patients who underwent interval debulking 
surgery, and 13.6 months (95% CI 11.3 to 14.9) in 128 
patients who had no surgery. In subgroup analyses according 
to age, median progression- free survival was 16.1 months 
(95% CI 14.5 to 18.5) in patients aged <70 years and 14.8 
months (95% CI 12.2 to 16.1) in those ≥70 years (Figure 2C). 
Age showed no clear prognostic effect for progression- free 
survival.
The best overall response was complete response in 63 
patients (21%) and partial response in 143 patients (48%), giving 
an objective response rate of 69% (95% CI 63% to 74%). An addi-
tional 70 patients (23%) achieved stable disease as their best 
response, resulting in a disease control rate of 92% (95% CI 89% 
to 95%). Objective response rate showed no difference according 
to age (69% (95% CI 63% to 75%) in patients aged <70 vs 68% 
(95% CI 56% to 78%) in patients aged ≥70 years). Likewise, 
disease control rates were almost identical (93% (95% CI 88% to 
96%) vs 91% (95% CI 83% to 96%) in younger vs older patients, 
respectively).
At the data cut- off, 105 patients (35%) had died (9 (15%) of the 
62 patients with primary debulking surgery, 41 (38%) of the 109 
with interval debulking surgery, and 55 (43%) of the 128 with no 
surgery) (see online supplementary figure S1). The 1- year overall 
survival rate in the overall population was 94% (95% CI 90% to 
96%). In subgroup analyses by age, 1- year overall survival rates 
were 94% (95% CI 90% to 97%) in patients aged <70 years versus 
91% (95% CI 83% to 96%) in patients aged ≥70 years.
Overall, 106 patients (35%) consented to the optional quality 
of life component of the study. At baseline, 87 patients (29%) 
completed questionnaires but there was rapid attrition, with only 
66 patients (22%) completing post- baseline questionnaires before 
5.5 months, and 59 (20%) between 5.5 and 9.5 months after base-
line. The available data showed no relevant changes from baseline 
in global health status, functioning, or symptom scales, except for 
improvements in role and social functioning (core module) and a 
transient increase in peripheral neuropathy symptoms (ovarian 
cancer module). However, the relatively low baseline participation 
rate and reduced participation over time limit the conclusions that 
can be drawn from this dataset.
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Figure 2 Progression- free survival: (A) overall population; (B) according to surgery; (C) according to age.
dISCuSSIOn
The safety profile of front- line bevacizumab- containing therapy in 
this UK- based observational study is consistent with findings from 
the two randomized phase III trials (GOG-0218 and ICON72 3) and 
the single- arm ROSiA study in the front- line setting.7 Most adverse 
events were typical of the chemotherapy regimen. Bevacizumab 
therapy was associated with hypertension, thromboembolic events, 
and low- grade bleeding and proteinuria, as expected according to 
previous studies in this setting.2 3 7–9 The incidence of gastrointes-
tinal perforation was low (1% grade ≥3). Adverse events were as 
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expected and no new safety signals emerged, despite administra-
tion of neoadjuvant bevacizumab in 36% of patients. This finding 
is consistent with published safety results from the GEICO 1205 
and ANTHALYA randomized phase II trials evaluating neoadjuvant 
bevacizumab; neither identified any particular safety concerns 
with neoadjuvant administration of bevacizumab.10 11 Hypertension 
and thromboembolic events were slightly more common in older 
than younger patients; this finding is consistent with the known 
increased risk of these events in older patients and those with 
pre- existing hypertension, irrespective of treatment, and is also 
consistent with findings from the ROSiA study.12
Median progression- free survival of 15.4 months (95% CI 14.5 to 
16.9) in this predominantly high- risk patient population receiving 
bevacizumab for 1 year replicates median progression- free survival 
of 16.0 months (95% CI 14.2 to 17.8) in the high- risk subgroup 
of the randomized phase III ICON7 trial.3 Our results are also very 
similar to recently published data from a prospective observational 
study in Japan (n=346), in which patients with stage III/IV newly 
diagnosed ovarian cancer received bevacizumab with carboplatin 
and paclitaxel, with bevacizumab continued for 22 cycles in total.13 
Median progression- free survival in the Japanese study was 
16.3 months (95% CI 14.5 to 18.9) . The response rate was 78% 
(95% CI 67% to 86%). In addition, a single- center retrospective 
analysis of 60 patients treated with front- line bevacizumab after 
primary debulking surgery or interval debulking surgery in South 
West Wales, UK, demonstrated median progression- free survival of 
16 months.14 Similar to OSCAR, some of these patients received 
bevacizumab in combination with single- agent carboplatin as 
they were not considered fit enough to receive combination 
chemotherapy.
On the other hand, median progression- free survival of 
15.4 months in the OSCAR study is shorter than the median 
progression- free survival of 21.3 months (95% CI 20.3 to 22.5) 
in the German OTILIA non- interventional study9 and 25.5 months 
(95% CI 23.7 to 27.6) in the international single- arm ROSiA 
study.7 Differences in dose, treatment duration, patient prog-
nosis, and surgery may all contribute to differences in median 
progression- free survival between the OSCAR, OTILIA, and ROSiA 
studies. For example, in OTILIA, all patients received bevaci-
zumab at 15 mg/kg for 15 months, and in ROSiA treatment was 
continued for up to 24 months. Furthermore, in the ROSiA study, 
23% of patients had stage I–IIIA disease, in contrast to OSCAR 
and OTILIA, which included only patients with stage IIIB–IV 
disease. Surgical differences were also apparent between coun-
tries: in the German OTILIA and global ROSiA studies, 94% (A 
Wegenaer, 2019, personal communication) and 95% of patients, 
respectively, underwent debulking surgery, and there was no 
visible residual disease after primary debulking surgery in 27% 
and 28% of patients, respectively,7 9 15 compared with 57% 
undergoing surgery and only 4% with no visible residual disease 
in the OSCAR study.
In our study population, only 21% of patients underwent primary 
debulking surgery, and a remarkable 43% received no surgery. 
Median progression- free survival was shortest in patients who 
received no surgery and longest in patients who underwent primary 
debulking surgery. One possible explanation for the low proportion 
of patients with surgery is that only patients ineligible for other 
clinical trials were enrolled in the OSCAR study, and therefore the 
population represents a particularly poor- prognosis subgroup. To 
test this hypothesis, one would need to collect data on all patients 
treated during the enrollment period. As highlighted by Phillips et 
al,16 outcomes in patients who do not receive standard therapy are 
rarely reported, but are typically considerably worse than in popula-
tions treated in prospective studies. In a cohort of 593 patients diag-
nosed with advanced ovarian cancer in a regional cancer center in 
Birmingham, UK, median overall survival was significantly shorter 
in the overall population than in patients who underwent surgery 
(30.2 vs 38.7 months; p<0.001); in patients undergoing primary 
debulking surgery, median overall survival was 54.5 months.16
The high proportion of patients with no surgery in the OSCAR 
study contrasts with the ICON7 population, in which all eligible 
stage III patients had to have primary surgery and only 2% (stage 
IV) had no surgery,17 perhaps making the replication of median 
progression- free survival in the OSCAR study more striking. It 
highlights an urgent need for quality control and improved surgical 
management of patients with ovarian cancer in the UK. British 
Gynecological Cancer Society clinical practice guidelines clearly 
state that the goal in managing advanced epithelial ovarian cancer 
is complete cytoreduction,18 and the need for specialist surgical 
training has been emphasized.19 Nevertheless, a recent audit of two 
gynecologic cancer centers in the UK illustrates the continued vari-
ation in surgical practice and its impact on outcomes.20
The main limitations of the OSCAR study are the lack of a control 
arm, the relatively short duration of follow- up, and the low partic-
ipation in quality of life assessments, which limits conclusions on 
the impact of treatment on patients. Major strengths are the rela-
tively large sample size and the inclusion of a patient population 
representing ‘real- life’ clinical practice, including patients deemed 
too unfit to receive combination chemotherapy (or surgery) and a 
substantial proportion of elderly patients. Finally, the consistency 
with progression- free survival observed with front- line bevaci-
zumab in the high- risk population of the randomized phase III 
ICON7 trial is noteworthy, confirming the applicability of these 
results to everyday practice.
Looking ahead, further data on front- line bevacizumab- containing 
therapy will be generated in the ongoing randomized phase III 
Medical Research Council ICON8B trial, as well as the control 
arms of the PAOLA-1 (NCT02477644), ENGOT- ov39/GOG-3015/
IMagyn050 (NCT03038100), ENGOT- ov43/BGOG (NCT03740165), 
and ENGOT- ov46/AGO/DUO- O (NCT03737643) trials.
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